vorasidenib
servier
['vorasidenib', 'indigo']
plenary session is underway! dr.mellinghoff from presents indigo: a practice changing ph3 study of vorasidenib vs placebo in pts w residual or recurrent grade 2 glioma with an idh1/2 mutation. big improvements in pfs, ttni- great for patients! #asco2023 
Physician Executive @providence; Head & Neck #Surgeon @provhealth; Member @chilesresearch focused on #immunotherapy. Tweets my own